Completed PHASE2 INTERVENTIONAL NCT00001287

Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Conditions Demyelinating Diseases Paraproteinemias

Interventions intravenous immunoglobulin (IVIg)

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Dec 31, 1990 Completion: Jan 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Demyelinating Diseases and Paraproteinemias and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 5 recorded versions since 1990 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Neurological Disorders and Stroke (NINDS)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States